New data published on DOR's orBec

DOR BioPharma, a US late-stage biopharmaceutical company developing products to treat side effects of cancer treatments and serious gastrointestinal diseases, has published a second summary of clinical trials on orBec (oral beclomethasone dipropionate) for the treatment of gastrointestinal graft-versus-host disease in the September issue of peer-reviewed journal Expert Opinion on Investigational Drugs.

The article states that, as a single agent, the response rates observed with orBec of 65%-77% are comparable to systemic corticosteroids. It also claims two randomized, double-blind, placebo-controlled trials indicate that orBec prevents the recurrence of acute GI GVHD and that the drug avoids the side effects of corticosteroids and shows an improved outcome in terms of transplant mortality.

"This is the fourth publication of our data in a well-regarded peer-reviewed journal," stated Christopher Schaber, chief executive of the firm. "We believe that publications such as these clearly highlight the importance of orBec to the hematopoietic cell transplantation community and help to reinforce the need for approval of this therapy in the treatment of acute GI GVHD," he added.